ASX Announcement 21 October 2026 Update on Commercial Terms for the Proposed Merger with Microba Life Sciences • Genetic Signatures Limited (ASX: GSS) (GSS) and Microba Life Sciences Limited (ASX: MAP) (Microba) have agreed, in principle, to revised terms for the proposed merger, under which...
Update on Commercial Terms for Proposed Merger with MAP
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The revised terms indicate that Microba shareholders will hold a larger percentage of the merged entity than previously stated, while existing Genetic Signatures shareholders will hold a smaller percentage. All other material terms of the merger remain unchanged and the transaction is progressing as planned.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Genetic Signatures Ltd. on 6ix
Story so far
Earlier from Genetic Signatures
- Response to Media Speculation & BCAL letter to GSS
- GSS: Response to Media Speculation & BCAL letter to GSS
- 2026 Notice of Annual General Meeting
- Quarterly Activities/Appendix 4C Cash Flow Report
- Becoming a substantial holder
Later from Genetic Signatures
- Addendum to Notice of Annual General Meeting
- Results of 2026 EGM and Appointment of Director
- BCAL Welcomes Dr John Melki's Appointment to GSS Board
- 3X Initial Directors Interest Notice
- Notification regarding unquoted securities - GSS
Follow Genetic Signatures into a list and get an email when it puts out news.
Follow Genetic Signatures